BISPECTRAL INDEX (BIS) GUIDED COMPARISON BETWEEN CLINICAL EFFECTS OF ETOMIDATE AND FENTANYL VERSUS DEXMEDETOMIDINE AND FENTANYL FOR CONSCIOUS SEDATION IN ERCP PROEDURE

Arpita Das1, Dipasri Bhattacharya2, Sankar Roy3, Anirban Ray4, Mohanchandra Mandal5

1Postgraduate Trainee, Department of Anaesthesiology, R. G. Kar Medical College and Hospital, Kolkata, West Bengal, India.
2Professor and HOD, Department of Anaesthesiology, R. G. Kar Medical College and Hospital, Kolkata, West Bengal, India.
3Assistant Professor, Murshidabad Medical College and Hospital, Murshidabad, West Bengal, India.
4Postgraduate Trainee, Department of Anaesthesiology, R. G. Kar Medical College and Hospital, Kolkata, West Bengal, India.
5Associate Professor, Department of Anaesthesiology, NRS Medical College and Hospital, Kolkata, West Bengal, India.

ABSTRACT

BACKGROUND

Endoscopic retrograde cholangiopancreatogram (ERCP) is recently being done under conscious sedation using intravenous anaesthetic agent and fentanyl. Dexmedetomidine, a new alpha 2 agonist with analgesic and sedative effects, is now being used to induce conscious sedation. 

The aim of this study was to compare BIS-guided time of onset of conscious sedation and recovery profile, haemodynamic effects, physician/patient satisfaction score and adverse events if any between patients receiving either etomidate-fentanyl or dexmedetomidine-fentanyl combination for undergoing ERCP procedure.

MATERIALS AND METHODS

This is a randomised controlled trial. One hundred patients scheduled for ERCP under BIS-guided conscious sedation were randomly allocated into two equal groups to receive either etomidate-fentanyl (Group E) or dexmedetomidine-fentanyl (Group-D). After premedication with midazolam (0.05 mg/kg), glycopyrrolate (0.2 mg) and fentanyl (1 mcg/kg), etomidate or dexmedetomidine were given to the patients allocated to the respective groups to attain a BIS score of 70. Sedation was maintained throughout the procedure by continuous infusion of these drugs. The time of onset and recovery from sedation, haemodynamic effects, physicians and patient’s satisfaction scores, pre- and post-operative serum cortisol and any adverse events were noted in the two groups.

RESULTS

The time of onset and recovery was earlier in E group (p=0.001). Incidence of myoclonus was significantly higher in E group (p=0.012). Physician and patient satisfaction were comparable in both the groups. There was no difference in pre-op and 12-hour post-op serum cortisol in either group.

CONCLUSION

BIS-guided etomidate-fentanyl for ERCP resulted in earlier onset and recovery from sedation with stable haemodynamics compared with dexmedetomidine-fentanyl.

KEY WORDS

BIS, Conscious Sedation, Dexmedetomidine, Etomidate, ERCP.


BACKGROUND

Endoscopic retrograde cholangiopancreatography (ERCP) is a commonly performed diagnostic and therapeutic procedure for various biliary tract and pancreatic diseases. The most significant advantage of this procedure is that it helps avoiding more traumatic and painful open surgical procedures. ERCP is frequently done under general anaesthesia with endotracheal intubation (With Muscle Relaxation).

This ensures immobilisation of the patient during the procedure and also helps protecting the airway. Now-a-days ERCP is being done under conscious sedation without muscle relaxation and without intubation. The most preferred position is semi-prone. In semi-prone position, chest wall compliance is decreased and diaphragm is displaced cephalad due to the increasing intra-abdominal pressure by external pressure applied on abdomen. This leads to a decrease in functional residual capacity and lung compliance, thereby compromising ventilation in anaesthetised or sedated patients. Increased intra-abdominal pressure decreases the venous return to the heart and predisposes the patient to the risk of hypotension. Maintaining the patient on spontaneous respiration without any upper airway obstruction (Under moderate/conscious sedation) is of utmost importance during the procedure. If the patient stops breathing spontaneously during the procedure, the patient has to be repositioned at the earliest followed by urgent resuscitation. During ERCP the

---

'Financial or Other Competing Interest': None.
Submission 28-12-2018, Peer Review 12-02-2019,
Corresponding Author: Sankar Roy,
Phulia, Shantipur,
Nadia, West Bengal, India.
E-mail: dr.sankar.roy2010@gmail.com
DOI: 10.14260/jems/2019/111
gastroenterologist and the anaesthesiologist share a common passage, the upper airway, so airway management can become troublesome at times.\textsuperscript{[2–5]}

Every procedure has its own advantages and disadvantages, which are to be carefully judged. The common adverse effects associated with ERCP are nausea, vomiting, throat bleeding and anxiety. Analgesia is also an important factor in the intra and post-operative period. An anxiety-free period before and adequate pain relief after the procedure increases the acceptability of ERCP, as a modality of management of various biliary and pancreatic diseases, amongst patients.\textsuperscript{[6,7]}

From anaesthetic point of view, patient positioning (Prone/semi-prone), lack of requirement of muscle relaxation and intubation, common adverse effects of gastroscopy (Nausea, vomiting, anxiety, throat bleed) and sharing a common passage (The upper airway) by the gastroenterologist and the anaesthesiologist, has made ERCP a challenge.

The administration of properly selected anaesthetic agents during ERCP can abolish upper airway reflexes and improve the comfort of patients during the procedure.\textsuperscript{[7–9]}

An ideal anaesthetic agent for ERCP should have the following properties:\textsuperscript{[8,9]}

- Rapid time of onset and recovery.
- Effective throughout the procedure with easy titration of drug delivery.
- Minimal adverse effects.

Conscious sedation is a drug induced depression of consciousness where no interventions are required to maintain the patency of airway with adequate spontaneous respiration and haemodynamic stability.

Etomidate has been used for procedural sedation because of its stable haemodynamic responses and short time of recovery. Dexmedetomidine is short acting and suitable for ERCP procedures because of better patient cooperation, haemodynamic stability and little or no respiratory depression.\textsuperscript{[8,9]} Use any of the two above mentioned drugs have their own merits and demerits.

Reasons Behind Selection of This Study-
1. Paucity of studies regarding ERCP procedures using etomidate/dexmedetomidine.
2. Anaesthesia in ERCP is a challenge.
3. Use of BIS for monitoring proper plane of sedation.

So, this study was done to compare the time of onset and recovery from conscious sedation using etomidate + fentanyl versus dexmedetomidine + fentanyl combination.

Etomidate causes adrenocortical suppression.\textsuperscript{[7,9]} Serum cortisol levels remain within the normal range and dysfunction resolves within 12-24 hours of using the drug. So, estimation of serum cortisol preoperatively and 12 hours later have been included as a parameter of this study.

Aims and Objectives

Aim of this study was to compare BIS-guided onset and recovery time of conscious sedation, potential complications and physician and patient satisfaction score between two anaesthetic combinations - etomidate + fentanyl and dexmedetomidine + fentanyl in patients undergoing ERCP.

MATERIALS AND METHODS

This was a randomised controlled trial. One hundred patients scheduled for ERCP under BIS guided conscious sedation were randomly allocated into two equal groups, E (Etomidate + fentanyl) and D (Dexmedetomidine + fentanyl). After premedication with midazolam (0.05 mg/kg), glycopyrrolate (0.2mg), fentanyl (1 mg/kg), etomidate and dexmedetomidine were given to the patients allocated to the respective groups to attain a BIS score of 70. Sedation was maintained throughout the procedure by continuous infusion of these drugs. The time of onset and recovery from sedation, haemodynamic effects and any adverse event were recorded. Physicians and patients were surveyed to assess their satisfaction regarding the anaesthetic procedure. Pre- and post-operative serum cortisol were studied. Study was done in Gastroenterology operating room (ERCP room) of a tertiary Medical College & Hospital from November 2016 to October 2017. All adult patients of ASA physical status I and II undergoing ERCP under conscious sedation during the study period were included fulfilling the inclusion criteria: Sample Size of 100 was taken for convenience.

They were randomised using computer generated random numbers and allocated into two groups, Group E and Group D as follows-
2. Group D: Patients receiving dexmedetomidine and fentanyl.

Inclusion Criteria

1. ASA physical status I and II of either sex.
2. Body weight: 40 – 70 kg.
3. Age: 20 – 60 years.

Exclusion Criteria

1. Associated comorbidities (Uncontrolled diabetes mellitus, uncontrolled hypertension, hypotension, morbid obesity, chronic kidney disease, any neurological/ liver disorder, COPD, congestive cardiac failure, low fixed cardiac output disorders, arrhythmias, shock, etc.)
2. Pregnancy and lactation.
3. Anticipated difficult intubation.
5. Uncooperative patients.
6. Patient refusal.
7. Allergy/history of adverse reaction to dexmedetomidine, etomidate and fentanyl.

Variables Studied

- **Parameters for Primary Objective**
  1. Time required to reach a BIS value of 70 from the beginning of drug infusion.
  2. Time required to reach a BIS value of ≥ 90 after stopping drug infusion.

- **Parameters for Secondary Objective**
  1. Heart rate, NIBP, SpO2, ECG monitoring intraoperatively.
2. Serum cortisol levels before and 12 hours after the procedure.
3. Myoclonus: yes/ no (Occurred or not)
   - PONV (Postoperative Nausea and Vomiting): YES/ NO (Occurred or not)
   - VAS (Visual Analogue Scale) score to assess severity of post-operative pain.
4. Physician and patient satisfaction grading (Good/ Fair/Poor)

**Methods of Data Collection**

- Detailed history taking.
- Proper clinical examination.
- Pre-procedure review of relevant investigation reports.
- Review of past medical records (if available)
- Intra operative recording of BIS values and vital parameters.
- Recording of any intraoperative adverse events (like Aponoea/ Myoclonus)
- Review of serum cortisol levels (Before and 12 hours after procedure)
- Post-operative nausea/ vomiting and post-operative pain.
- Interview regarding patient and physician satisfaction during post-operative period.

**Pre-Procedural Investigations**

1. Haemoglobin.
2. Complete blood counts.
3. Serum urea/ creatinine.
4. Fasting and postprandial blood sugar.
5. Liver function test (Including P-Time/ INR)
6. Serum sodium/ potassium.
7. Serology (HBsAg, anti HCV, HIV)
8. Chest X Ray (PA view)
9. ECG (12 leads)
10. Other targeted investigations (if required)

Gastroenterologists selected the cases that were planned for ERCP procedure on OPD basis, from patients admitted in the Gastroenterology and other wards (In response to referrals done for consultation). A proper pre-anaesthetic check-up was done.

**Detailed History Taken**

1. ASA physical status assessed.
2. METs (Metabolic equivalents) score assessed.
3. Mallampati Score, Mouth Opening, Neck Movement assessed.
4. Presence of any loose tooth/ artificial dentures enquired about.
5. All suspected cases of difficult airway identified.
6. Complete general and systemic examination.
7. All investigation reports and past medical reports evaluated.
8. Any further specific investigations, if thought necessary, ordered and evaluated.
9. All patients were ordered to follow the ASA Fasting Guidelines on the morning of the procedure.
10. Patients were advised about continuing/ avoiding their regular medication (as needed).

11. Patients and their near relatives were counselled thoroughly.
12. Informed written consent was obtained.

On the day of the procedure, patients came to the ERCP room with an attendant. The patients and their near relatives were thoroughly re-counseled regarding the procedure and the anaesthetic technique to be used. Pre-anaesthetic check-up sheet was checked. Boyle’s anaesthesia machine and Bain breathing system were duly checked. All necessary drugs and equipment were kept ready. Difficult airway cart and all resuscitation equipment and drugs were kept ready. The patients, who were selected for the study depending on the exclusion and inclusion criteria, were allocated into 2 groups:

1. **Group-E**: Patients receiving etomidate and fentanyl.
2. **Group-D**: Patients receiving dexmedetomidine and fentanyl.

Intravenous (IV) access was secured with 18 G IV cannula under aseptic precautions. Blood samples were taken for the estimation of pre-operative Serum Cortisol. Intravenous fluid was started. Patients were then assisted to lie prone on the procedure table with a soft wedge under their right shoulder, right thigh flexed, head turned to the right side (45 deg.) on pillow avoiding compression of the dependent (left) eye.

NIBP, ECG, Pulse Oximeter (SpO2), BIS monitor were attached.

Supplemental oxygen was given to the patients via a nasal cannula at a rate of 2 L/ min. A mouth guard was inserted. All baseline haemodynamic parameters were documented. All the patients were pre-medicated with Inj. glycopyrrolate (0.2 mg) IV and Inj. fentanyl(1-2 mcg/kg). Group-E patients were given a bolus dose of etomidate @ 0.15 – 0.2 mg/kg and then infusion of etomidate was started @ 0.01-0.03 mg/kg/min to attain a BIS value of 70 and maintain it during the procedure. Group-D patients were given bolus of dexmedetomidine of about 1 mcg/kg over 10 minutes and then infusion was started @ 0.4-1 mcg/kg/min to attain a BIS value of 70 and maintain that throughout the procedure. Induction time (i.e., the time from start of bolus injection to the time at which a BIS value of 70 was attained) was noted. Inj. hyoscine 20mg IV was given to patients prior to insertion of the guide wire to facilitate sphincter dilatation. All haemodynamic parameters were continuously monitored intra-operatively. Occurrence of any adverse haemodynamic effects were noted and managed accordingly. During the procedure the patients were monitored for occurrence of any adverse effects. These adverse effects were documented and managed adequately. All patients were given Inj. ondansetron 0.15 mg/kg slow IV for prophylaxis of postoperative nausea and vomiting (PONV). At the completion of the procedure, the drug infusion was stopped. Recovery time was recorded from the cessation of drug infusion till BIS score reaches ≥ 90. The patient was shifted to the post-recovery room when the BIS score was ≥ 90. Patients were monitored in the recovery room. They were discharged to the ward when the modified Aldrete Score was ≥ 9. All the patients were interviewed regarding their experience relating to the procedure and anaesthesia. They were asked about level of satisfaction, Post-operative pain (VAS score) and occurrence of PONV. After 12 hours of the procedure, the patient’s blood sample was sent for Serum Cortisol. Physician’s satisfaction was also assessed. Patients
were adequately monitored in the ward for early detection of post-ERCP complications. The data were analysed using Statistical Package for Social Sciences version 22.0 for Windows (IBM Corp. Released 2011. IBM SPSS Statistics for Windows, Version 20.0. Armonk, NY: IBM Corp.) The continuous variables (Age, Height, Weight, Time regarding the onset of sedation and recovery from sedation, postoperative pain scores and serum cortisol levels) between the groups were analysed using Student’s unpaired t-test. Intra-group comparison of pre-operative and post-operative serum cortisol levels were analysed using paired t-test. The categorical variables such as gender distribution, ASA-physical status, haemodynamics events (Hypotension, Hypertension and Bradycardia), adverse events (apnoea, mydronus, PONV), patient’s satisfaction and physician’s satisfaction were analysed using the Pearson Chi-square test. A P-value < 0.05 was taken to be statistically significant.

RESULTS

Two groups were comparable with respect to demographic data.

<table>
<thead>
<tr>
<th></th>
<th>Group-D (n = 50)</th>
<th>Group-E (n = 50)</th>
<th>p Value</th>
<th>Statistical Significance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (In Years)</td>
<td>50.74 ± 6.337</td>
<td>51.28 ± 6.095</td>
<td>0.001</td>
<td>Not significant</td>
</tr>
<tr>
<td>Sex (F/M)</td>
<td>25 (50%) / 25 (50%)</td>
<td>24 (48%) / 26 (52%)</td>
<td>0.004</td>
<td>Not significant</td>
</tr>
<tr>
<td>Weight (in Kgs.)</td>
<td>56.42 ± 7.089</td>
<td>61.58 ± 6.000</td>
<td>0.001</td>
<td>Not significant</td>
</tr>
<tr>
<td>Height (in cms)</td>
<td>160.06 ± 7.742</td>
<td>160.18 ± 7.639</td>
<td>0.002</td>
<td>Not significant</td>
</tr>
<tr>
<td>ASA-PS (I/II)</td>
<td>24 (48%) / 26 (52%)</td>
<td>20 (40%) / 30 (60%)</td>
<td>0.004</td>
<td>Not significant</td>
</tr>
</tbody>
</table>

Table 1. Demographic Data

There was significant difference between the times of onset of sedation as well as recovery from sedation between the two groups. Onset as well as recovery was significantly earlier in the group receiving etomidate-fentanyl.

<table>
<thead>
<tr>
<th></th>
<th>Group-D (n = 50)</th>
<th>Group-E (n = 50)</th>
<th>p Value</th>
<th>Statistical Significance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Onset (In Seconds)</td>
<td>87.475 ± 80.68</td>
<td>84.59 ± 3.69</td>
<td>0.000</td>
<td>Significant</td>
</tr>
<tr>
<td>Recovery (In Seconds)</td>
<td>586.51 ± 104.51</td>
<td>494.05 ± 44.57</td>
<td>0.000</td>
<td>Significant</td>
</tr>
</tbody>
</table>

Table 2. Comparison of Onset and Recovery Time of Sedation Between the Two Study Groups

![Figure 1. Time of Onset and Recovery from Sedation](Time in Seconds)

Onset and recovery were faster in etomidate group compared to dexmedetomidine group.

<table>
<thead>
<tr>
<th></th>
<th>Group-D (n = 50)</th>
<th>Group-E (n = 50)</th>
<th>p Value</th>
<th>Statistical Significance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypotension (Yes/No)</td>
<td>1 (2%) / 49 (98%)</td>
<td>0 / 50 (100%)</td>
<td>0.315</td>
<td>Not Significant</td>
</tr>
<tr>
<td>Hypertension (Yes/No)</td>
<td>6 (12%) / 44 (88%)</td>
<td>0 / 50 (100%)</td>
<td>0.012</td>
<td>Significant</td>
</tr>
<tr>
<td>Bradycardia (Yes/No)</td>
<td>3 (6%) / 47 (94%)</td>
<td>0 / 50 (100%)</td>
<td>0.079</td>
<td>Not Significant</td>
</tr>
</tbody>
</table>

Table 3. Comparison of Haemodynamic Parameters Between the Two Study Groups

There was a significant incidence of hypertension in D group.

<table>
<thead>
<tr>
<th></th>
<th>Group-D (n = 50)</th>
<th>Group-E (n = 50)</th>
<th>p Value</th>
<th>Statistical Significance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Apnoea (Yes/No)</td>
<td>1 (2%) / 49 (98%)</td>
<td>1 (2%) / 49 (98%)</td>
<td>1.000</td>
<td>Not Significant</td>
</tr>
<tr>
<td>Mydronus (Yes/No)</td>
<td>0 / 50 (100%)</td>
<td>5 (10%) / 45 (90%)</td>
<td>0.022</td>
<td>Significant</td>
</tr>
<tr>
<td>P.O.N.V. (Yes/No)</td>
<td>2 (4%) / 48 (96%)</td>
<td>6 (12%) / 44 (88%)</td>
<td>0.140</td>
<td>Not Significant</td>
</tr>
</tbody>
</table>

Table 4. Adverse Events

There was a significant incidence of mydronus in E group.

<table>
<thead>
<tr>
<th></th>
<th>Group D (n=50)</th>
<th>Group E (n=50)</th>
<th>p Values (Inter-Group Analysis)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre-Op. Cortisol (mcg/dl)</td>
<td>13.41 ± 0.81</td>
<td>13.57 ± 0.83</td>
<td>0.698</td>
</tr>
<tr>
<td>Post-Op. Cortisol (mcg/dl)</td>
<td>13.54 ± 0.70</td>
<td>13.54 ± 0.70</td>
<td>0.710</td>
</tr>
</tbody>
</table>

p Values (Intra-Group Analysis of Pre-Op and Post-Op Parameters) 0.731 0.734

Pre-operative as well as post-operative serum cortisol levels between the two groups (inter-group) were analysed using Student’s unpaired t-test. Again, the intra-group comparisons were done between the pre-operative and post-operative serum cortisol levels in each group using paired t-test. P<0.05, not significant.

Table 5. Pre-Operative And 12 Hours Post-Operative Serum Cortisol in Two Groups

There was no significant difference between the pre-operative and 12-hour post-operative levels of serum cortisol in the group of patients who received etomidate.

<table>
<thead>
<tr>
<th>Patient Satisfaction</th>
<th>Group-D (n = 50)</th>
<th>Group-E (n = 50)</th>
<th>p Value</th>
<th>Statistical Significance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Poor (1)</td>
<td>2 (4%)</td>
<td>6 (12%)</td>
<td>Not Significant</td>
<td></td>
</tr>
<tr>
<td>Fair (2)</td>
<td>18 (36%)</td>
<td>13 (26%)</td>
<td>0.244</td>
<td>Not Significant</td>
</tr>
<tr>
<td>Good (3)</td>
<td>30 (60%)</td>
<td>31 (62%)</td>
<td>Not Significant</td>
<td></td>
</tr>
</tbody>
</table>

Table 6. Comparison in Level of Patient’s Satisfaction

There was no significant difference with respect to the level of patient’s satisfaction between the two study groups.
There was no significant difference with respect to the level of physician's satisfaction between the two study groups.

DISCUSSION

ERCP is a non-operating room day care procedure. Painless endoscopy will improve the patient’s compliance for ERCP and hasten the diagnosis, help treatment of a few biliary pancreatic diseases and help palliation in inoperable cases.[10,11] 

Bispectral index (BIS) is used to measure the level of sedation. BIS is a reasonable way to monitor the depth of sedation in patients receiving sedation/general anaesthesia. It ensures proper titration of anaesthetic agents and helps to avoid adverse effects due to overdose as well as avoid awareness due to inappropriate dosing.[12-14]

In the present study the two study groups were comparable in terms of demographic data.

There was a significant difference in the time of onset (time required to attain a BIS score of 70) (p-value 0.000) and time of recovery (time to attain a BIS score of 90) (p-value 0.000) between the two groups. There was significantly earlier onset of sedation as well as earlier recovery from sedation in etomidate-fentanyl group. Thus, it was found that etomidate-fentanyl combination resulted in earlier onset and shorter duration of sedation, consistent with the study carried out by El-Shmaa NS and El-Baradey GF in the year 2014.[15]

Possible reasons behind the above results are[16]
- Short initial distribution half-life of etomidate.
- Rapid clearance by liver.
- Etomidate is rapidly metabolised by liver into inactive by-products.
- Rapid renal and biliary clearance of the metabolites.

Rise or fall of Mean Arterial Pressure (MAP) by ≥ 20% from baseline value of MAP was considered as hypertension or hypotension and bradycardia when heart rate was < 60/minute. In a pre-study trial, high incidence of hypertension was found with dexmedetomidine given as a rapid infusion.[17] Though dexmedetomidine is a α2 selective agonist (α1: α2 = 1: 1600, approximately), α1 effects may be seen with high plasma concentrations or high infusion rate of the drug.[18] So, in our study, the loading dose of dexmedetomidine was given over 10 minutes which conform with the study done by Xu J et al in 2015.[19] We found a significant occurrence of hypertension in the group receiving dexmedetomidine-fentanyl (p-value = 0.012). This hypertension mostly occurred after giving the loading dose of dexmedetomidine/just after the onset of sedation and gradually settled over time. No active intervention was needed for management of this hypertension. The possible cause of this hypertension was α1 mediated vasoconstriction in high plasma concentrations/at high infusion rates of dexmedetomidine. There was no statistically significant difference in the incidences of hypotension and bradycardia between the two study groups. Incidence of hypotension was not significant in either of the two study groups. Etomidate lacks effect on the sympathetic nervous system and on the function of baroreceptors, so it is haemodynamically stable.[10] Thus, etomidate administration for sedation during ERCP resulted in more stable haemodynamics and shorter recovery. This finding was consistent with the study done by Toklu S et al in the year 2009.[19] Dexmedetomidine is also cardiostable in nature. It can occasionally cause hypotension but only with large intravenous loading doses.[16,20] Use of dexmedetomidine was found to maintain haemodynamic stability, as it was seen in a study by Patel CR et al.[21]

There was no significant difference in the incidence of apnoea between the two groups. This observation was consistent with the fact that both etomidate and dexmedetomidine are known to cause little/no depression in ventilation.[16,22] There was no significant difference in the incidences of post-operative nausea and vomiting between the two study groups. Possible cause being, all patients received Inj. ondansetron towards the end of the procedure. Post-operative pain, as assessed with the Visual analogue scale (VAS), was comparable in both the groups. Patients of both groups were seen to experience mild pain in the post-operative period. This was probably due to the administration of fentanyl in all patients irrespective of their group of allocation. Fentanyl causes analgesia by µ opioid receptor mediated direct inhibition of the ascending transmission of nociceptive stimuli from spinal cord dorsal horn.[23] Although there was no significant difference (p-value = 0.131) between the incidence of post-operative pain in the two groups, the VAS Score in Group-D was slightly lower than Group-E. This could be because dexmedetomidine has an inherent analgesic effect mediated through stimulation of α2C/ 2A receptor in dorsal horn and by directly suppressing pain transmission by reducing release of nociceptive transmitters and hyperpolarization of interneurons,[16] whereas etomidate has no analgesic effect of its own. Myoclonus is a prominent adverse effect experienced during the induction of anaesthesia with etomidate. The incidence of myoclonus has been reported to be as high as 50-80%, especially if etomidate is used without premedication.[24] The incidence of myoclonus after induction of sedation using etomidate can be reduced by using midazolam, fentanyl or a combination of midazolam-fentanyl as pre-treatment.[24,25] In our study 10% of the patients (5 out of 50 patients) induced with etomidate experienced myoclonus. This was a significant finding of the study (p-value = 0.022).

Use of etomidate has been known to result in adrenocortical dysfunction due to dose dependent reversible inhibition of 11β hydroxylase, leading to decreased biosynthesis of cortisol. Clinical impact of this adrenal suppressive effect is doubtful.[16] However, the serum cortisol levels remain within the normal range and dysfunction resolves within 12-24 hours of using the drug,[7,9] as it has been shown in multiple studies. There was no significant difference between the pre-operative and 12-hour post-operative serum cortisol between the two groups. The pre-operative and 12-hour post-operative serum cortisol in

<table>
<thead>
<tr>
<th>Physician Satisfaction</th>
<th>Group-D (n = 50)</th>
<th>Group-E (n = 50)</th>
<th>p Value</th>
<th>Statistical Significance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Poor (1)</td>
<td>1 (2%)</td>
<td>6 (12%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fair (2)</td>
<td>18 (36%)</td>
<td>12 (24%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Good (3)</td>
<td>31 (62%)</td>
<td>32 (64%)</td>
<td>0.091</td>
<td>Not significant</td>
</tr>
</tbody>
</table>

Table 7. Comparison in Level of Physician’s Satisfaction
Group-E was also comparable (p-value = 0.734). This finding was consistent with the study done by Srivastava et al.\(^7\)

There was no significant difference between the two study groups with respect to the level of patient and physician satisfaction.

**CONCLUSION**

Etomidate-fentanyl combination for ERCP resulted in earlier onset and early recovery from sedation with stable haemodynamics when compared to dexmedetomidine-fentanyl combination.

**REFERENCES**